NASDAQ:HOTH Hoth Therapeutics 8/12/2025 Earnings Report $1.60 +0.15 (+9.93%) Closing price 03:59 PM EasternExtended Trading$1.62 +0.01 (+0.62%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Hoth Therapeutics EPS ResultsActual EPS-$0.17Consensus EPS -$0.27Beat/MissBeat by +$0.10One Year Ago EPSN/AHoth Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHoth Therapeutics Announcement DetailsQuarterDate8/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsHoth Therapeutics' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Hoth Therapeutics Earnings HeadlinesHoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin ToxicitiesSeptember 10 at 8:29 AM | prnewswire.comHoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug DevelopmentSeptember 4, 2025 | prnewswire.comNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. Its hardware is in such high demand that in just one data center, there's enough of it to stretch around the Earth eight timesSeptember 10 at 2:00 AM | InvestorPlace (Ad)Hoth Therapeutics stock soars on positive preclinical data for cancer drugSeptember 3, 2025 | za.investing.comHoth Therapeutics, Inc.: Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results ...September 2, 2025 | finanznachrichten.deEXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven CancersSeptember 2, 2025 | finance.yahoo.comSee More Hoth Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hoth Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hoth Therapeutics and other key companies, straight to your email. Email Address About Hoth TherapeuticsHoth Therapeutics (NASDAQ:HOTH) is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure. Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization. Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.Written by Jeffrey Neal JohnsonView Hoth Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
